Sleep apnea combo therapy shows promise in early trial

NCT ID NCT07577661

Not yet recruiting Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining a nerve-stimulating implant with two medications (atomoxetine and oxybutynin) can improve breathing during sleep more than either treatment alone. Twenty-four adults with obstructive sleep apnea who already have the implant will try each combination in random order. The goal is to see if the combo reduces breathing pauses better than the implant or medication by itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: hypoglossal nerve stimulation device and atomoxetine plus oxybutynin
What this could lead to: If it works, this could point toward a more effective treatment for obstructive sleep apnea that combines a device and medication.
What could go wrong: This is a very small, early-phase trial with only 24 people. The combination may not work better than either treatment alone, and the medications can cause side effects like dry mouth or dizziness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSTRUCTIVE SLEEP APNEA SLEEP DISORDERED BREATHING

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.